Selective anti-cancer agents as anti-aging drugs

Cancer Biology and Therapy

Volumn 14, Issue 12, 2013, Pages 1092-1097

  Blagosklonny, Mikhail V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Aging; Cancer; Geroconversion; Gerosuppression; MTOR; Rapalogs; Rapamycin

Indexed keywords

ADENYLATE KINASE; ANTINEOPLASTIC AGENT; CARCINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAPAMYCIN DERIVATIVE; RAS PROTEIN; SOMATOMEDIN; TRANSCRIPTION FACTOR FOXO;

ADAPTATION; AGING; ARTICLE; CANCER CELL; CANCER PREVENTION; CANCER RESISTANCE; CANCER THERAPY; DRUG TARGETING; GENETIC HETEROGENEITY; HUMAN; LONGEVITY; MITOSIS; NEOPLASM; SIGNAL TRANSDUCTION; DRUG EFFECTS; METABOLISM; NEOPLASMS;

AGING; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84891773586     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.27350     Document Type: Article

References (176)

1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-;42; PMID:11287973; http://dx.doi.org/10.1056/NEJM20010405344140-;2 (Pubitemid 32267973)
2. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112:4808-;17; PMID:19064740; http://dx.doi.org/10.1182/blood- 2008-07-07795-;8
3. Druker BJ. Perspectives on the development of imatinib and the future of cancer research. Nat Med 2009; 15:1149-52; PMID:19812576; http://dx.doi.org/10. 1038/nm1009-114-;9
4. Sawyers CL. The 2011 Gordon Wilson Lecture: overcoming resistance to targeted cancer drugs. Trans Am Clin Climatol Assoc 2012; 123:114-23, discussion 123-5; PMID:2330397-;9
5. Cozma D, Thomas-Tikhonenko A. Kit-activating mutations in AML: lessons from PU.1-induced murine erythroleukemia. Cancer Biol Ther 2006; 5:579-81; PMID:16760643; http://dx.doi.org/10.4161/cbt.5.6.287-;3 (Pubitemid 44024709)
6. Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005; 4:747-52; PMID:15970668; http://dx.doi.org/10.4161/cbt.4.7.182-;6 (Pubitemid 41351174)
7. Blagosklonny MV. STI-571 must select for drugresistant cells but 'no cell breathes fire out of its nostrils like a dragon'. Leukemia 2002; 16:570-;2; PMID:11960334; http://dx.doi.org/10.1038/sj.leu.240240-;9 (Pubitemid 34449735)
8. Blagosklonny MV. Oncogenic resistance to growthlimiting conditions. Nat Rev Cancer 2002; 2:221-5; PMID:11990858; http://dx.doi.org/10.1038/nrc74-;3
9. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5:13-7; PMID:14749122; http://dx.doi.org/10.1016/S1535-6108(03)00336- ;2 (Pubitemid 38121592)
10. Glickman MS, Sawyers CL. Converting cancer therapies into cures: lessons from infectious diseases. Cell 2012; 148:1089-98; PMID:22424221; http://dx.doi.org/10.1016/j.cell.2012.02.01-;5
11. Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013; 2:e00747; PMID:23805382; http://dx.doi.org/10.7554/eLife.0074-;7
12. Blagosklonny MV. Antagonistic drug combinations that select against drug resistance: from bacteria to cancer. Cancer Biol Ther 2007; 6:1013-4; PMID:17646740; http://dx.doi.org/10.4161/cbt.6.7.434-;0 (Pubitemid 351574949)
13. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget 2011; 2:1352-67; PMID:2226746-;2
14. Danilov A, Shaposhnikov M, Plyusnina E, Kogan V, Fedichev P, Moskalev A. Selective anticancer agents suppress aging in Drosophila. Oncotarget 2013; 4:1507-26; PMID:2409669-;7
15. Doonan R, McElwee JJ, Matthijssens F, Walker GA, Houthoofd K, Back P, Matscheski A, Vanfleteren JR, Gems D. Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans. Genes Dev 2008; 22:3236-;41; PMID:19056880; http://dx.doi.org/10.1101/gad.50480-;8
16. Gems D, Partridge L. Genetics of longevity in model organisms: debates and paradigm shifts. Annu Rev Physiol 2013; 75:621-44; PMID:23190075; http://dx.doi.org/10.1146/annurev-physiol-030212-18371-;2
17. Blagosklonny MV. Answering the ultimate question "what is the proximal cause of aging?". Aging (Albany NY) 2012; 4:861-77; PMID:2342577-;7
18. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) 2011; 3:1130-41; PMID:2224614-;7
19. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-;84; PMID:16469695; http://dx.doi.org/10.1016/j. cell.2006.01.01-;6 (Pubitemid 43199434)
20. Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev 2013; 23:53-62; PMID:23317514; http://dx.doi.org/10.1016/j.gde. 2012.12.00-;5
21. Loewith R, Hall MN. Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics 2011; 189:1177-201; PMID:22174183; http://dx.doi.org/ 10.1534/genetics.111.13336-;3
22. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35; PMID:21157483; http://dx.doi.org/10.1038/nrm302-;5
23. Hands SL, Proud CG, Wyttenbach A. mTOR's role in ageing: protein synthesis or autophagy? Aging (Albany NY) 2009; 1:586-97; PMID:2015754-;1
24. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 2012; 4:159-65; PMID:2239461-;4
25. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, Lithgow GJ, Campisi J. MicroRNAs miR-146a/b negatively modulate the senescence- associated inflammatory mediators IL-6 and IL-8. Aging (Albany NY) 2009; 1:402-11; PMID:2014818-;9
26. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6:2853-;68; PMID:19053174; http://dx.doi.org/10. 1371/journal.pbio.006030-;1
27. Blagosklonny MV. Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog- like gerosuppression? Aging (Albany NY) 2012; 4:450-5; PMID:2286901-;6
28. Driscoll MK, Albanese JL, Xiong ZM, Mailman M, Losert W, Cao K. Automated image analysis of nuclear shape: what can we learn from a prematurely aged cell? Aging (Albany NY) 2012; 4:119-32; PMID:2235476-;8
29. Hubackova S, Krejcikova K, Bartek J, Hodny Z. IL1- and TGFβ-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine 'bystander senescence'. Aging (Albany NY) 2012; 4:932-51; PMID:2338506-;5
30. Tominaga-Yamanaka K, Abdelmohsen K, Martindale JL, Yang X, Taub DD, Gorospe M. NF90 coordinately represses the senescence-associated secretory phenotype. Aging (Albany NY) 2012; 4:695-708; PMID:2311762-;6
31. Cahu J, Bustany S, Sola B. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis 2012; 3:e446; PMID:23254289; http://dx.doi.org/10.1038/cddis.2012.18-;3
32. Georgakopoulou EA, Tsimaratou K, Evangelou K, Fernandez Marcos PJ, Zoumpourlis V, Trougakos IP, Kletsas D, Bartek J, Serrano M, Gorgoulis VG. Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues. Aging (Albany NY) 2013; 5:37-50; PMID:2344953-;8
33. Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging (Albany NY) 2012; 4:166-75; PMID:2241193-;4
34. Leontieva OV, Demidenko ZN, Blagosklonny MV. MEK drives cyclin D1 hyperelevation during geroconversion. Cell Death Differ 2013; 20:1241-;9; PMID:23852369; http://dx.doi.org/10.1038/cdd.2013.8-;6
35. Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) 2010; 2:924-35; PMID:2121246-;5
36. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A 2010; 107:9660-4; PMID:20457898; http://dx.doi.org/10.1073/pnas.100229810-;7
37. Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A 2012; 109:13314-8; PMID:22847439; http://dx.doi.org/10.1073/pnas.120569010-;9
38. Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, et al. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol 2012; 181:278-93; PMID:22698676; http://dx.doi.org/10.1016/j.ajpath.2012.03.01-;7
39. Dulic V. Be quiet and you'll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence? Aging (Albany NY) 2011; 3:3-4; PMID:2124837-;3
40. Zhao H, Halicka HD, Li J, Darzynkiewicz Z. Berberine suppresses gero-conversion from cell cycle arrest to senescence. Aging (Albany NY) 2013; 5:623-36; PMID:2397485-;2
41. Gan B, DePinho RA. mTORC1 signaling governs hematopoietic stem cell quiescence. Cell Cycle 2009; 8:1003-6; PMID:19270523; http://dx.doi.org/10.4161/ cc.8.7.804-;5
42. Kofman AE, McGraw MR, Payne CJ. Rapamycin increases oxidative stress response gene expression in adult stem cells. Aging (Albany NY) 2012; 4:279-89; PMID:2252933-;4
43. Blagosklonny MV. Hormesis does not make sense except in the light of TOR-driven aging. Aging (Albany NY) 2011; 3:1051-62; PMID:2216672-;4
44. Blagosklonny MV. Prospective treatment of agerelated diseases by slowing down aging. Am J Pathol 2012; 181:1142-6; PMID:22841821; http://dx.doi.org/10. 1016/j.ajpath.2012.06.02-;4
45. Blagosklonny MV. Once again on rapamycininduced insulin resistance and longevity: despite of or owing to. Aging (Albany NY) 2012; 4:350-8; PMID:2268366-;1
46. Blagosklonny MV. How to save Medicare: the antiaging remedy. Aging (Albany NY) 2012; 4:547-52; PMID:2291570-;7
47. Guarente L, Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature 2000; 408:255-62; PMID:11089983; http://dx.doi.org/10.1038/ 3504170-;0
48. Pinkston JM, Garigan D, Hansen M, Kenyon C. Mutations that increase the life span of C. elegans inhibit tumor growth. Science 2006; 313:971-;5; PMID:16917064; http://dx.doi.org/10.1126/science.112190-;8 (Pubitemid 44267389)
49. Sinclair DA, Guarente L. Unlocking the secrets of longevity genes. Sci Am 2006; 294:48-51, 54-7; PMID:16502611; http://dx.doi.org/10.1038/ scientificamerican0306-4-;8
50. Kaeberlein M, Kennedy BK. Hot topics in aging research: protein translation and TOR signaling, 2010. Aging Cell 2011; 10:185-90; PMID:21176090; http://dx.doi.org/10.1111/j.1474-9726.2010.00665.x
51. Stanfel MN, Shamieh LS, Kaeberlein M, Kennedy BK. The TOR pathway comes of age. Biochim Biophys Acta 2009; 1790:1067-74; PMID:19539012; http://dx.doi.org/10.1016/j.bbagen.2009.06.00-;7
52. Naiman S, Kanfi Y, Cohen HY. Sirtuins as regulators of mammalian aging. Aging (Albany NY) 2012; 4:521-2; PMID:2291570-;6
53. Flynn JM, O'Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, Zykovich A, Mooney SD, Strong R, Rosen CJ, et al. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 2013; 12:851-62; PMID:23734717; http://dx.doi.org/10.1111/acel.1210-;9
54. Rongo C. Epidermal growth factor and aging: a signaling molecule reveals a new eye opening function. Aging (Albany NY) 2011; 3:896-905; PMID:2193117-;9
55. Williams TW, Dumas KJ, Hu PJ. EAK proteins: novel conserved regulators of C. elegans lifespan. Aging (Albany NY) 2010; 2:742-7; PMID:20975207
56. Polymenis M, Kennedy BK. Chronological and replicative lifespan in yeast: do they meet in the middle? Cell Cycle 2012; 11:3531-2; PMID:22951539; http://dx.doi.org/10.4161/cc.2204-;1
57. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326:140-4; PMID:19797661; http://dx.doi.org/10.1126/science.117722-;1
58. Partridge L, Gems D. Mechanisms of ageing: public or private? Nat Rev Genet 2002; 3:165-75; PMID:11972154; http://dx.doi.org/10.1038/nrg75-;3
59. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493:338-45; PMID:23325216; http://dx.doi.org/10.1038/nature1186-;1
60. Kaeberlein M. Longevity and aging. F1000Prime Rep 2013; 5:5; PMID:23513177; http://dx.doi.org/10.12703/P5-;5
61. Ramadori G, Coppari R. Does hypothalamic SIRT1 regulate aging? Aging (Albany NY) 2011; 3:325-8; PMID:2146451-;8
62. Kenyon CJ. The genetics of ageing. Nature 2010; 464:504-12; PMID:20336132; http://dx.doi.org/10.1038/nature0898-;0
63. Borrás C, Monleón D, López-Grueso R, Gambini J, Orlando L, Pallardó FV, Santos E, Viña J, Font de Mora J. RasGrf1 deficiency delays aging in mice. Aging (Albany NY) 2011; 3:262-76; PMID:2142249-;8
64. Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 2006; 5:2087-102; PMID:17012837; http://dx.doi.org/10.4161/cc.5.18.328-;8 (Pubitemid 44566240)
65. Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today 2007; 12:218-24; PMID:17331886; http://dx.doi.org/10.1016/j.drudis.2007.01.00-;4
66. Tsang CK, Qi H, Liu LF, Zheng XFS. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007; 12:112-;24; PMID:17275731; http://dx.doi.org/10.1016/j. drudis.2006.12.00-;8 (Pubitemid 46176669)
67. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011; 23:744-55; PMID:21963299; http://dx.doi.org/10.1016/j.ceb.2011.09.00-;3
68. Zhao C, Vollrath D. mTOR pathway activation in age-related retinal disease. Aging (Albany NY) 2011; 3:346-7; PMID:2148303-;9
69. Nair S, Ren J. Autophagy and cardiovascular aging: lesson learned from rapamycin. Cell Cycle 2012; 11:2092-9; PMID:22580468; http://dx.doi.org/10.4161/ cc.2031-;7
70. Ye L, Widlund AL, Sims CA, Lamming DW, Guan Y, Davis JG, Sabatini DM, Harrison DE, Vang O, Baur JA. Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance. Aging (Albany NY) 2013; 5:539-50; PMID:2392988-;7
71. Blagosklonny MV. Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives. Aging (Albany NY) 2010; 2:265-73; PMID:2051978-;1
72. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging (Albany NY) 2009; 1:281-8; PMID:2015751-;7
73. Eide CA, Druker BJ, O'Hare T. Kinase inhibitor therapy in CML: it's what's inside that counts. Oncotarget 2013; 4:1332-3; PMID:2393476-;3
74. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351-6; PMID:19029981; http://dx.doi.org/10.1038/nm.189-;0
75. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483:613-7; PMID:22425996; http://dx.doi.org/10.1038/nature1093-;7
76. Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget 2012; 3:118-31; PMID:2239276-;5
77. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 2013; 14:e60-9; PMID:23369684; http://dx.doi.org/10.1016/ S1470-2045(12)70539-;9
78. Nucera C, Lawler J, Hodin R, Parangi S. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget 2010; 1:751-6; PMID:2132138-;4
79. Robert G, Jullian V, Jacquel A, Ginet C, Dufies M, Torino S, Pottier A, Peyrade F, Tartare-Deckert S, Bourdy G, et al. Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway. Oncotarget 2012; 3:1688-99; PMID:2351879-;6
80. Shih HJ, Chen HH, Chen YA, Wu MH, Liou GG, Chang WW, Chen L, Wang LH, Hsu HL. Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity. Oncotarget 2012; 3:1401-15; PMID:2321146-;6
81. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, et al. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 2013; 4:153-62; PMID:2384772-;2
82. Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther 2012; 13:1244-54; PMID:22895079; http://dx.doi.org/10.4161/cbt. 2146-;0
83. Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE, Kinzler KW, Huso DL, Vogelstein B, Papadopoulos N. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci U S A 2010; 107:2598-;603; PMID:20133737; http://dx.doi.org/10.1073/pnas.091401810-;7
84. Deming DA, Leystra AA, Farhoud M, Nettekoven L, Clipson L, Albrecht D, Washington MK, Sullivan R, Weichert JP, Halberg RB. mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers. PLoS One 2013; 8:e60709; PMID:23593290; http://dx.doi.org/10.1371/journal.pone.006070-;9
85. Chung S, Suzuki H, Miyamoto T, Takamatsu N, Tatsuguchi A, Ueda K, Kijima K, Nakamura Y, Matsuo Y. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget 2012; 3:1629-40; PMID:2328330-;5
86. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2:833-49; PMID:2206483-;3
87. Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010; 20:427-;34; PMID:20399660; http://dx.doi.org/10.1016/j. tcb.2010.03.00-;4
88. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20:267-75; PMID:16452501; http://dx.doi.org/10.1101/gad.136320-;6 (Pubitemid 43200281)
89. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2010; 2:344-52; PMID:2060625-;2
90. Vigneron A, Vousden KH. p53, ROS and senescence in the control of aging. Aging (Albany NY) 2010; 2:471-4; PMID:2072956-;7
91. Hall MN. Talks about TORCs: recent advancesin target of rapamycin signalling. On mTOR nomenclature. Biochem Soc Trans 2013; 41:887-;8; PMID:23863150; http://dx.doi.org/10.1042/BST2013009-;2
92. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10:457-;68; PMID:12408816; http://dx.doi.org/10.1016/S1097-2765(02)00636-;6 (Pubitemid 35284167)
93. Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K, Gray NS, Turk BE, Yaffe MB, Sabatini DM. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 2013; 341:1236566; PMID:23888043; http://dx.doi.org/10.1126/science.123656-;6
94. Garber K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst 2001; 93:1517-9; PMID:11604470; http://dx.doi.org/10. 1093/jnci/93.20.151-;7 (Pubitemid 32998477)
95. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22; PMID:17613433; http://dx.doi.org/10.1016/j. ccr.2007.05.00-;8 (Pubitemid 47001784)
96. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, et al.; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-;81; PMID:17538086; http://dx.doi.org/10.1056/NEJMoa06683- ;8 (Pubitemid 46849157)
97. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5:671-88; PMID:16883305; http://dx.doi.org/10.1038/nrd206-;2 (Pubitemid 44151605)
98. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4:335-;48; PMID:15122205; http://dx.doi.org/10.1038/nrc136- ;2 (Pubitemid 38579480)
99. Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011; 2:510-7; PMID:2168095-;4
100. Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, et al. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget 2012; 3:1615-28; PMID:2327104-;4
101. Janes MR, Fruman DA. Targeting TOR dependence in cancer. Oncotarget 2010; 1:69-76; PMID:2065774-;1
102. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha- Paul SA, Moulder SL, et al. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 2012; 3:1566-75; PMID:2324815-;6
103. Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol Ther 2012; 13:1349-54; PMID:23151465; http://dx.doi.org/10.4161/ cbt.2285-;9
104. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581-9; PMID:16434506; http://dx.doi.org/10.1681/ASN.200509099-;3
105. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317-23; PMID:15800227; http://dx.doi.org/10.1056/NEJMoa04283-;1 (Pubitemid 40411498)
106. Mártinez JM, Pulido LB, Bellido CB, Usero DD, Aguilar LT, Moreno JL, Artacho GS, Díez-Canedo JS, Gómez LM, Bravo MA. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation. Transplant Proc 2010; 42:641-3; PMID:20304212; http://dx.doi.org/10.1016/j.transproceed.2010.02.01-;1
107. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, et al.; TUMORAPA Study Group. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367:329-;39; PMID:22830463; http://dx.doi.org/10.1056/NEJMoa120416- ;6
108. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-9; PMID:22149876; http://dx.doi.org/10.1056/NEJMoa110965-;3
109. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011; 108:1556-63; PMID:21952069; http://dx.doi.org/10.1111/j.1464-410X.2011.10629.x
110. Major P. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging (Albany NY) 2011; 3:189-91; PMID:2141546-;2
111. Masiello D, Mohi MG, McKnight NC, Smith B, Neel BG, Balk SP, Bubley GJ. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol Ther 2007; 6:195-201; PMID:17218776; http://dx.doi.org/10.4161/cbt.6.2.358-;8 (Pubitemid 46641623)
112. Francipane MG, Lagasse E. Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget 2013; Forthcoming; PMID:24185040.
113. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009; 8:3831-7; PMID:19901542; http://dx.doi.org/10.4161/cc.8.23.1007-;0
114. Don AS, Zheng XF. Recent clinical trials of mTORtargeted cancer therapies. Rev Recent Clin Trials 2011; 6:24-35; PMID:20868343; http://dx.doi.org/10.2174/15748871179398014-;7
115. De P, Miskimins K, Dey N, Leyland-Jones B. Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope. Cancer Treat Rev 2013; 39:403-12; PMID:23352077; http://dx.doi.org/10.1016/j. ctrv.2012.12.00-;2
116. Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 2012; 11:594-;603; PMID:22262166; http://dx.doi.org/10.4161/cc.11.3.1909-;6
117. Keniry M, Parsons R. mTOR inhibition, the second generation: ATP-competitive mTOR inhibitor initiates unexpected receptor tyrosine kinase-driven feedback loop. Cancer Discov 2011; 1:203-4; PMID:22586570; http://dx.doi.org/10.1158/2159-;8290.CD-11-015-;7
118. Liu Q, Kang SA, Thoreen CC, Hur W, Wang J, Chang JW, Markhard A, Zhang J, Sim T, Sabatini DM, et al. Development of ATP-competitive mTOR inhibitors. Methods Mol Biol 2012; 821:447-60; PMID:22125084; http://dx.doi.org/10.1007/978- 1-61779-430-8-2-;9
119. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009; 69:6232-40; PMID:19584280; http://dx.doi.org/10. 1158/0008-5472.CAN-09-029-;9
120. Gilley R, Balmanno K, Cope CL, Cook SJ. Adaptation to chronic mTOR inhibition in cancer and in aging. Biochem Soc Trans 2013; 41:956-;61; PMID:23863163; http://dx.doi.org/10.1042/BST2013008-;0
121. Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 2010; 107:12469-;74; PMID:20616057; http://dx.doi.org/10.1073/pnas.100511410-;7
122. Ayyadevara S, Alla R, Thaden JJ, Shmookler Reis RJ. Remarkable longevity and stress resistance of nematode PI3K-null mutants. Aging Cell 2008; 7:13-22; PMID:17996009; http://dx.doi.org/10.1111/j.1474-9726.2007.00348.x
123. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4:988-;1004; PMID:16341064; http://dx.doi.org/10.1038/nrd190-;2
124. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6:184-92; PMID:16453012; http://dx.doi.org/10.1038/nrc181-;9 (Pubitemid 43292562)
125. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27:5497-510; PMID:18794884; http://dx.doi.org/10.1038/onc. 2008.24-;5
126. Liu D, Hou P, Liu Z, Wu G, Xing M. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009; 69:7311-9; PMID:19706758; http://dx.doi.org/10.1158/0008-;5472. CAN-09-107-;7
127. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-44; PMID:19644473; http://dx.doi.org/10.1038/nrd292-;6
128. Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, Ohyashiki K. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biol Ther 2014; Forthcoming; PMID:24100660; http://dx.doi.org/10.4161/cbt.2672-;5
129. Dbouk HA, Backer JM. A beta version of life: p110β takes center stage. Oncotarget 2010; 1:729-33; PMID:2132138-;2
130. Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget 2010; 1:578-82; PMID:2131745-;3
131. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010; 1:530-43; PMID:2131744-;9
132. Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, Gabelli SB, Kinzler KW, Vogelstein B, Huso DL, et al. PI3Kα inhibitors that inhibit metastasis. Oncotarget 2010; 1:339-48; PMID:2117939-;8
133. Gojo I, Perl A, Luger S, Baer MR, Norsworthy KJ, Bauer KS, Tidwell M, Fleckinger S, Carroll M, Sausville EA. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Invest New Drugs 2013; 31:1217-27; PMID:23443507; http://dx.doi.org/10.1007/s10637-013-9937-;8
134. Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, et al. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 2012; 118:6055-62; PMID:22674198; http://dx.doi.org/10.1002/cncr.2766-;8
135. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006; 5:766-70; PMID:16760642; http://dx.doi.org/10.4161/cbt.5.7.287-;4 (Pubitemid 44775131)
136. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013; 6:27; PMID:23587417; http://dx.doi.org/10.1186/1756-8722-6-2-;7
137. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al.; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107-14; PMID:22663011; http://dx.doi.org/10.1056/NEJMoa120342-;1
138. Lee L, Niu H, Rueger R, Igawa Y, Deutsch J, Ishii N, Mu S, Sakamoto Y, Busse-Reid R, Gimmi C, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker. Clin Cancer Res 2009; 15:7368-74; PMID:19934286; http://dx.doi.org/10.1158/1078- 0432.CCR-09-169-;6
139. Metro G, Chiari R, Baldi A, De Angelis V, Minotti V, Crinò L. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-smallcell lung cancer. Future Oncol 2013; 9:167-77; PMID:23414467; http://dx.doi.org/10.2217/fon.12.19-;8
140. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012; 11:909-20; PMID:22389471; http://dx.doi.org/10.1158/1535-;7163.MCT-11-098-;9
141. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012; 3:1068-111; PMID:2308553-9
142. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013; 31:482-9; PMID:23248257; http://dx.doi.org/10.1200/JCO.2012.43.596-6
143. Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 2013; 4:1090-9; PMID:24055054; http://dx.doi.org/10.1016/j.celrep.2013.08.02-3
144. Yoshida T, Kakegawa J, Yamaguchi T, Hantani Y, Okajima N, Sakai T, Watanabe Y, Nakamura M. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2. Oncotarget 2012; 3:1533-45; PMID:2323777-3
145. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. Combined BRAF and MEK inhibition in
146. Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol 2012; 132:1850-9; PMID:22437314; http://dx.doi.org/10.1038/jid.2012.6-3
147. Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2011; 2:336-46; PMID:2150522-8
148. Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol 2013; Forthcoming; PMID:23879247; http://dx.doi.org/10.1111/ijd.1220-5
149. King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, Smitheman KN, Erhardt JA, Hughes-Earle A, Kane-Carson LS, et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One 2013; 8:e67583; PMID:23844038; http://dx.doi.org/10.1371/journal.pone.006758-3
150. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, Blagosklonny MV, Gudkov AV. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY) 2012; 4:709-14; PMID:2312361-6
151. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, Gudkov AV, Antoch MP. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY) 2012; 4:715-22; PMID:2311759-3
152. Donehower LA. Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency. Aging (Albany NY) 2012; 4:660-1; PMID:2312835-9
153. Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C, Strong R, Bokov A, Javors MA, Ikeno Y, et al. Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors. Aging (Albany NY) 2013; 5:100-10; PMID:2345483-6
154. Mosley JD, Poirier JT, Seachrist DD, Landis MD, Keri RA. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol Cancer Ther 2007; 6:2188-97; PMID:17699716; http://dx.doi.org/10.1158/1535-7163.MCT-07-023-5 (Pubitemid 47294747)
155. Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, Veenstra TD, Issaq HJ, Linnoila RI, Dennis PA. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 2007; 13:2281-9; PMID:17404113; http://dx.doi.org/10.1158/1078-0432. CCR-06-257-0 (Pubitemid 46649898)
156. Stelzer MK, Pitot HC, Liem A, Lee D, Kennedy GD, Lambert PF. Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila) 2010; 3:1542-51; PMID:21149330; http://dx.doi.org/10.1158/1940-6207. CAPR-10-022-8
157. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, et al. Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature 2009; 460:392-6; PMID:1958768-0
158. Robinson J, Lai C, Martin A, Nye E, Tomlinson I, Silver A. Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. J Pathol 2009; 219:35-40; PMID:19434632; http://dx.doi.org/10.1002/path.256-2
159. Athar M, Kopelovich L. Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention. Cancer Prev Res (Phila) 2011; 4:957-61; PMID:21733819; http://dx.doi.org/10.1158/1940-6207.CAPR-11-026-6
160. Liu Y, Huang Y, Wang Z, Huang Y, Li X, Louie A, Wei G, Mao JH. Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development. Aging (Albany NY) 2013; 5:111-9; PMID:2345486-8
161. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40:685-93; PMID:16125352; http://dx.doi.org/10.1016/j. exger.2005.07.00-7 (Pubitemid 41265819)
162. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY) 2010; 2:760-74; PMID:2108472-9
163. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008; 7:2769-73; PMID:18728386; http://dx.doi.org/10.4161/cc.7.17.662-5
164. Menendez JA, Cufí S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez-Martin A. Gerosuppressant metformin: less is more. Aging (Albany NY) 2011; 3:348-62; PMID:2148304-0
165. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, Minor RK, Blouin MJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun 2013; 4:2192; PMID:23900241; http://dx.doi.org/10.1038/ncomms319-2
166. Mikheev AM, Stoll EA, Ramakrishna R, Mikheeva SA, Horner PJ, Rostomily RC. Geropotency: increased malignant potential of aging neural progenitors. Aging (Albany NY) 2012; 4:854-5; PMID:2325754-5
167. Greaves M. Leukemogenesis and ageing: 'fit for transformation'? Aging (Albany NY) 2011; 3:79-80; PMID:2138613-0
168. Henry CJ, Marusyk A, DeGregori J. Aging-associated changes in hematopoiesis and leukemogenesis: what's the connection? Aging (Albany NY) 2011; 3:643-56; PMID:2176520-1
169. Vicente-Dueñas C, Abollo-Jiménez F, Ruiz-Roca L, Alonso-Escudero E, Jiménez R, Cenador MB, Criado FJ, Cobaleda C, Sánchez-García I. The age of the target cell affects B-cell leukaemia malignancy. Aging (Albany NY) 2010; 2:908-13; PMID:2116422-1
170. DePinho RA. The age of cancer. Nature 2000; 408:248-54; PMID:11089982; http://dx.doi.org/10.1038/3504169-4
171. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Kovalenko IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011; 3:148-57; PMID:2138612-9
172. Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY) 2012; 4:320-9; PMID:2258923-7
173. Ikeno Y, Bronson RT, Hubbard GB, Lee S, Bartke A. Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci 2003; 58:291-6; PMID:12663691; http://dx.doi.org/10.1093/gerona/58.4.B29-1 (Pubitemid 36397045)
174. Berrigan D, Perkins SN, Haines DC, Hursting SD. Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. Carcinogenesis 2002; 23:817-22; PMID:12016155; http://dx.doi.org/10.1093/carcin/ 23.5.81-7
175. Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci 2010; 31:89-98; PMID:20097433; http://dx.doi.org/10.1016/j. tips.2009.11.00-4
176. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther 2008; 7:1520-4; PMID:18769112; http://dx.doi.org/10.4161/cbt.7.10.666-3